A Phase II trial studying PTC Therapeutics’ PTC518 in Huntington’s disease (HD) has been paused in the United States following a request from the FDA for additional data, the company announced Tuesday afternoon.
https://www.pharmalive.com/wp-content/uploads/2022/10/BioSpaceBrainscans10-19-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-19 16:54:272022-10-20 11:24:20PTC runs into latest Huntington’s roadblock with US trial pause
